ALLMedicine™ Acute Myeloid Leukemia Center

Jan 20th, 2022 - MicroRNA-199a (miR-199a) inhibits the progression of several hematological malignancies and enhances the sensitivity to chemotherapy in acute myeloid leukemia (AML), but its clinical role in AML needs further investigation. This study aimed to exp...

Jan 20th, 2022 - This study evaluated venetoclax population pharmacokinetics (popPK) in patients with treatment-naïve acute myeloid leukemia (AML) and assessed the relationship between venetoclax exposure and clinical response for venetoclax in combination with ei...

Jan 19th, 2022 - Considering treatment changes and an improved prognosis of non-Hodgkin lymphoma (NHL) over time, knowledge regarding long-term health outcomes including late effects of treatment have become increasingly important. We report on time trends of seco...

Jan 19th, 2022 - Idarubicin 12 mg/m2 has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of idarubicin can improve the remission rate. This phase 2 prospective single-arm study enrolled 45 adul...

Jan 19th, 2022 - Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are characterized by risk of relapses, poor survival, unwanted side effects and high toxicity with the current therapies. In light of these facts, there are efforts to develop new dr...

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

Jan 14th, 2022 - Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recom...

Jan 14th, 2022 - The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as mai...

Jan 14th, 2022 - This is a phase 2, non-randomized, interventional, open-label, multicenter trial evaluating the efficacy of VEN-AZA as a bridge-to-transplant therapy in chemotherapy-treated adult NPM1mut AML patients who experience molecular relapse or progressio...

Jan 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the toxicities of navtemadlin (KRT-232 [AMG-232]) in combination with decitabine (20 mg/m^2 for 10 days), and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of KRT-232 (AMG-232) in c...

Jan 13th, 2022 - The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated ti...

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

Jan 4th, 2022 - Ciltacabtagene autoleucel (cilta-cel) elicited a 97.9% objective response rate (ORR) and an 82.5% stringent complete response (sCR) rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up, accor...

Jan 4th, 2022 - The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to updated findings ...

Jan 4th, 2022 - Switch maintenance therapy with bevacizumab (Avastin) or PARP inhibitors, such as olaparib (Lynparza), niraparib (Zejula), or rucaparib (Rubraca), has improved outcomes for patients with platinum-sensitive recurrent ovarian cancer, said Richard Pe...

Jan 3rd, 2022 - Angela Alistar, MD Medical Director Gastrointestinal Medical Oncology Morristown Medical Center A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the ope...